LALPATHLAB - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 2.9
| Stock Code | LALPATHLAB | Market Cap | 22,193 Cr. | Current Price | 1,325 ₹ | High / Low | 1,771 ₹ |
| Stock P/E | 41.4 | Book Value | 140 ₹ | Dividend Yield | 0.91 % | ROCE | 31.2 % |
| ROE | 25.4 % | Face Value | 10.0 ₹ | DMA 50 | 1,403 ₹ | DMA 200 | 1,461 ₹ |
| Chg in FII Hold | -1.57 % | Chg in DII Hold | 0.98 % | PAT Qtr | 113 Cr. | PAT Prev Qtr | 146 Cr. |
| RSI | 37.8 | MACD | -20.3 | Volume | 1,07,480 | Avg Vol 1Wk | 2,16,622 |
| Low price | 1,176 ₹ | High price | 1,771 ₹ | PEG Ratio | 3.17 | Debt to equity | 0.06 |
| 52w Index | 25.1 % | Qtr Profit Var | 7.24 % | EPS | 30.8 ₹ | Industry PE | 36.9 |
📊 Dr. Lal PathLabs (LALPATHLAB) shows weak intraday potential today. RSI at 37.8 indicates oversold conditions but lacks strong reversal signals. MACD is negative (-20.3), confirming bearish sentiment. Current price (1,325 ₹) is below both 50 DMA (1,403 ₹) and 200 DMA (1,461 ₹), reflecting short-term weakness. Volume (1,07,480) is well below average (2,16,622), limiting breakout potential.
💡 Optimal Buy Price: 1,320–1,330 ₹ (near support)
🎯 Profit-Taking Levels: 1,350–1,370 ₹ (short-term resistance)
🛑 Stop-Loss: 1,310 ₹ (recent low)
⏳ If already holding intraday: Exit near 1,350–1,360 ₹ if momentum weakens or if price fails to sustain above 1,330 ₹ with volume confirmation.
Positive
- Strong ROCE (31.2%) and ROE (25.4%) indicate efficient capital use.
- Debt-to-equity ratio of 0.06 reflects near debt-free status.
- Dividend yield of 0.91% provides shareholder returns.
- DII holdings increased (+0.98%), showing domestic institutional support.
- 52-week performance is strong (+25.1%).
Limitation
- Stock trading below both 50 DMA and 200 DMA indicates bearish trend.
- Quarterly PAT declined from 146 Cr. to 113 Cr.
- FII holdings decreased (-1.57%), reflecting reduced foreign investor confidence.
- High P/E (41.4) compared to industry average (36.9), suggesting overvaluation.
- Volume below average, limiting intraday opportunities.
Company Negative News
- No major negative news reported, but weak technicals and declining quarterly profits weigh on sentiment.
Company Positive News
- EPS of 30.8 ₹ highlights earnings strength.
- DII inflows indicate domestic confidence in the company.
Industry
- Industry P/E at 36.9 is slightly lower than Lal PathLabs’ 41.4, suggesting relative overvaluation.
- Diagnostics sector remains resilient, supported by healthcare demand but faces pricing pressures and competition.
Conclusion
⚠️ Lal PathLabs is not an ideal intraday candidate today due to weak momentum, declining profits, and price trading below key averages. Short-term traders may attempt a bounce trade near 1,320–1,330 ₹ with a tight stop-loss at 1,310 ₹, but risk remains elevated. Conservative traders should avoid aggressive intraday positions until momentum indicators improve.